{"podcast":{"title":"Hematologic Oncology Update","slug":"hematologic-oncology-update-916423","podcast_index_feed_id":916423,"rss_url":"https://feeds.captivate.fm/hematologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/hematologic-oncology","image_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png","author":"Dr. Neil Love","episode_count":161,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.","last_synced_at":"2026-09-26T04:24:25.521627+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423"},"episode":{"title":"For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress","slug":"for-oncology-nurses-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-proceedings-from-the-2026-annual-ons-congress","published_at":"2026-07-16T18:15:00+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/for-oncology-nurses-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-proceedings-from-the-2026-annual-ons-congress","show_page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423","url":"https://hematologic-oncology.captivate.fm/episode/6114-ons2026-nhlcll","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/91312b52-b9a3-4bb2-b973-7090e4b22762.mp3","summary":"Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications","meta_description":"Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7106,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/for-oncology-nurses-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-proceedings-from-the-2026-annual-ons-congress/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/for-oncology-nurses-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-proceedings-from-the-2026-annual-ons-congress.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}